Strong Performance in Q3 2024
DocGo recorded $138.7 million in revenue and $17.9 million in adjusted EBITDA. The company has more than doubled the number of assigned lives in their care gap closure programs, now exceeding 500,000 patients.
Increased Guidance for 2024
2024 revenue guidance has been fine-tuned to $620 million to $630 million, and adjusted EBITDA is expected to be $70 million to $75 million. Cash flow from operations is now projected to be $90 million to $100 million, up from $80 million to $90 million.
Successful Expansion and New Contracts
DocGo is expanding its care gap closure programs and has signed an expansion deal with L.A. Care to provide transitional care management and other services.
Strong Cash Position
DocGo's cash and cash equivalents increased to over $108 million, up from $86 million last quarter and $59 million in Q1 of 2024.
Improved Gross Margins
The adjusted gross margin was 36%, up from 29.5% in Q3 2023. Mobile Health segment margins improved to 38.8% from 28.8%.